Maternal and FetaL Outcomes in the ERa of ModulatorS
C
Cynthia Brown, MD
Primary Investigator
Overview
To characterize changes in FEV1 over the course of pregnancy based on cumulative CFTR modulator use while pregnant along with defining other factors that may influence changes in pulmonary function
Description
This is a prospective, multi-center, observational study to follow pregnant women with CF and their infants who are exposed to highly effective CFTR modulators, but will also include unexposed pregnant mothers with CF and their infants. The women will be followed over the course of pregnancy and 2 years post-delivery. The infants will also be followed for 2 years after delivery.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
pregnancy, cystic fibrosis
-
Age: Between 16 Years - 100 Years
-
Gender: Female
Inclusion Criteria:
- Must be ≥ 16 years of age at Enrollment visit.
- B. Currently pregnant (i.e., either positive in-home pregnancy test with an absence of negative confirmatory pregnancy test or positive in-clinic pregnancy test).
- C. Planning to continue with pregnancy.
Exclusion Criteria:
- Participants who fail to meet one or more of the eligibility criteria will not be enrolled in this study. Waivers of any of the above study entry criteria will not be granted.
Updated on
05 May 2024.
Study ID: 11628; MAYFLOWERS-OB-20
Please visit our main page to search for other studies you may be interested in.
If you need help finding a study or have any questions, please contact us at inhealth@iu.edu
